CD163
CD163 Molecule Information
Name：Scavenger receptor cysteine-rich type 1 protein M130
Target Synonym：CD163?M130?Hemoglobin scavenger receptor
Number of Launched Drugs：1
Number of Drugs in Clinical Trials：1
Lastest Research Phase：Approved
| Cat. No. |
Species |
Product Description |
Structure |
Purity |
Feature |
| CD3-H52E8 |
Human |
Human CD163 Protein |
|
|
|
CD163 Molecule Synonym Name
CD163,M130
CD163 Molecule Background
Scavenger receptor cysteine-rich type 1 protein M130 (CD163) is also known as hemoglobin scavenger receptor, which is a scavenger receptor for the hemoglobin-haptoglobin complex. CD163 has also been shown to mark cells of monocyte/macrophage lineage. A soluble form of the receptor exists in plasma, commonly denoted sCD163. sCD163 is generated by ectodomain shedding of the membrane bound receptor. sCD163 is upregulated in a large range of inflammatory diseases including liver cirrhosis, type 2 diabetes, macrophage activation syndrome, Gaucher's disease, sepsis, HIV infection, rheumatoid arthritis and Hodgkin Lymphoma.
CD163 References
CD163 Public Drug Information
| Name |
Research Code |
Research Phase |
Company |
First Brand Name |
First Approved Country |
First Indication |
First Approved Company |
First Approved Date |
Indications |
Clinical Trials |
| Tetrachlorodecaoxide |
OXO-K993; TCDO; WF-10 |
Approved |
NuvOx, Crescita Therapeutics |
|
|
|
|
|
Inflammation, Allergic rhinitis (AR), Immunological disorders |
Details
|
CD163 Clinical Drug Information
| Name |
Research Code |
Research Phase |
Company |
Indications |
Clinical Trials |
| TBI-304 |
HRC-304; TBI-304H; TBI-304 |
Phase Ⅰ |
Hemosol BioPharma |
Chemotherapy-induced anaemia |
Details
|
A-Z
